Pharma’s AI Investment Signals New Drug Discovery Paradigm
From improved molecular design to AI-driven automation, waves of AI tools promise to accelerate therapeutic development. Still, skeptics…
After 1- and 6-Month Gains, Gene Editing Companies Await Q3 Results
As developers of gene editing therapies and other genetic medicines get set to report third quarter earnings in…